



**Docket File Information**  
**SAFETY INSPECTION REPORT**  
**AND COMPLIANCE INSPECTION**

1. LICENSEE <b>Cancer Care Group, P.C.</b> REPORT <b>2007-001</b>	2. NRC/REGIONAL OFFICE <b>Region III</b> <b>2443 Warrenville Road, Suite 210</b> <b>Lisle, IL 60532</b>
--	--

3. DOCKET NUMBER(S) 030-36525	4. LICENSE NUMBER(S) 13-32500-01	5. DATE(S) OF INSPECTION June 8, 2007
----------------------------------	-------------------------------------	--

6. INSPECTION PROCEDURES USED 87132	7. INSPECTION FOCUS AREAS 03.01, 03.02, 03.03, 03.04, 03.05, 03.06, 03.07, and 03.08
--	---

**SUPPLEMENTAL INSPECTION INFORMATION**

1. PROGRAM CODE(S) 02230	2. PRIORITY G 2	3. LICENSEE CONTACT James Currier, M.D., RSO	4. TELEPHONE NUMBER 317-925-7730
-----------------------------	--------------------	---	-------------------------------------

Main Office Inspection      Next Inspection Date: June 2009

Field \_\_\_\_\_

Temporary Job Site \_\_\_\_\_

**PROGRAM SCOPE**

This licensee was private multi-speciality out-patient cancer care clinic. The licensee was authorized use Ir-192 in an HDR unit. The radiation therapy department was staffed with 2 medical physicists, 2 physicians (authorized users) and 6 therapy technologists. The licensee administered approximately 1-2 patient treatment series monthly using its HDR unit; these treatments were for prostate and gynecological cancers. All HDR patient treatments were administered by the attending radiation oncologist and the medical physicist (therapy technologists did not operate the controls to the HDR unit). Source exchange, maintenance, and repairs on the HDR unit were performed by the manufacturer.

This inspection consisted of interviews with selected licensee personnel, a review of selected records, tour of the radiation oncology department, and independent measurements. The inspector observed one HDR brachytherapy treatment. The inspector reviewed the written directive for the procedure; observed the licensee performing daily QA checks and treatment planning; and observed the patient treatment and patient surveys at the conclusion of the treatment. The inspector also interviewed the physician authorized user and the nurse who attended the patient.